India’s Drug Controller General has granted marketing authorization for Takeda’s Qdenga (TAK-003), marking the nation’s first authorized dengue vaccine. The authorization covers individuals aged 4 to 60 without requiring pre-vaccination serological testing. This approval arrives as India’s reported annual dengue cases have surged more than elevenfold over the past two decades, exceeding 233,000 cases in 2024.
Regulatory Landscape and Vaccine Differentiation
The approval of Qdenga positions the vaccine differently than its predecessor, Dengvaxia. According to Takeda, the primary clinical advantage of Qdenga is its “serostatus-agnostic” label. This allows for administration without the need for pre-vaccination screening, a process that is often impractical in high-transmission regions.
Sanofi’s Dengvaxia remains authorized in the U.S. and EU but is restricted to patients with confirmed prior dengue infection. Sanofi has moved to discontinue global distribution of the vaccine due to low demand. Meanwhile, Brazil’s Instituto Butantan has developed a similar live-attenuated tetravalent candidate, which has also received domestic approval for a broad, screening-free population.
Did you know?
Qdenga is built on a dengue serotype 2 genetic backbone. By substituting envelope and pre-membrane genes from the other three serotypes, the vaccine produces four chimeric viruses designed to trigger immune responses against all four circulating dengue strains.
Clinical Trial Data and Long-Term Efficacy
The authorization in India is supported by both the local Phase III DEN-302 study and the global pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES). Takeda identifies TIDES as the largest and longest efficacy trial conducted for a dengue vaccine.
Seven-year follow-up data from the TIDES trial demonstrate sustained protection against virologically confirmed dengue and hospitalizations. However, Takeda notes that efficacy levels vary depending on the specific serotype and the baseline serostatus of the individual receiving the vaccine.
Global Deployment and Future Rollout Strategy
Since its initial launch in 2022, Qdenga has received authorization in 43 countries, including Indonesia, Thailand, Malaysia, and Vietnam. More than 32 million doses have been distributed globally through both public and private health programs, according to Takeda.
The World Health Organization (WHO) has recommended the use of the vaccine without pre-vaccination screening since 2023. Additionally, the vaccine holds WHO prequalification, which facilitates procurement through international health bodies like UNICEF and PAHO. Regarding the rollout in India, Takeda has not yet disclosed specific launch dates, pricing, or whether the vaccine will be integrated into the government’s public immunization schedule or restricted to the private market.
Frequently Asked Questions
Is pre-vaccination testing required for Qdenga?
No. Unlike previous dengue vaccines, Qdenga is authorized for use in individuals aged 4 to 60 without the need for screening to confirm prior exposure.
How many countries have authorized Qdenga?
As of the latest reports, the vaccine has been authorized in 43 countries, including several nations across Asia, Latin America, and Europe.
What is the primary difference between Qdenga and Dengvaxia?
The main distinction is the label; Qdenga does not require pre-vaccination screening, whereas Dengvaxia is restricted to those with a confirmed history of dengue infection.
For deeper insights into the immunology behind vaccine development, explore the AllSci platform.
Have questions about vaccine policy or disease prevention? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on global health developments.
Worth a look